11.1 Information on toxicological effects
Acute toxicity
LD50 Oral - 5.1 mg/kg
LC50 Inhalation - 4 h - 0.05 mg/l
LD50 Dermal - 51 mg/kg
Skin corrosion/irritation
Remarks: No data available
Serious eye damage/eye irritation
Remarks: No data available
Respiratory or skin sensitization
Classified based on available data. For more details, see section 2
Germ cell mutagenicity
Classified based on available data. For more details, see section 2
Carcinogenicity
Classified based on available data. For more details, see section 2
Reproductive toxicity
Classified based on available data. For more details, see section 2
Specific target organ toxicity - single exposure
Classified based on available data. For more details, see section 2
Specific target organ toxicity - repeated exposure
Classified based on available data. For more details, see section 2
Aspiration hazard
Classified based on available data. For more details, see section 2
11.2 Additional Information
RTECS: TF8750000
Cholinesterase inhibitors can cause heavy salivation and secretion in the lungs, lachrymation, blurred vision, involuntary defecation, diarrhea, tremor, ataxia, sweating, hypothermia, lowered heart rate, and/or a fall in blood pressure as a re- sult of their action at cholinergic nerve sites., Headache, Nausea, Vomiting, Dizzi- ness, Drowsiness, Confusion., Weakness, Muscle cramps/spasms., To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.